Literature DB >> 19647110

Is GPR55 an anandamide receptor?

Andrew J Brown1, C Robin Hiley.   

Abstract

Anandamide activates CB(1) cannabinoid receptors but also has effects, particularly in the vasculature, that cannot be explained by actions at either this or the other cloned cannabinoid receptor, the CB(2) receptor. These effects are probably mediated by a novel G protein-coupled receptor, but genome searching has not revealed a strong candidate. Several approaches have suggested that an orphan receptor, GPR55, is a target for anandamide, but the pharmacology of this receptor is such that it cannot be categorically identified as a cannabinoid receptor. GPR55 appears primarily to be a receptor for lysophosphatidylinositol which may exhibit biased agonism, leading to it also responding to anandamide. GPR55 activates G(alpha12) and G(alpha13) and thence RhoA, leading to an oscillatory intracellular Ca(2+) signal. Further complexity arises from possible interactions between the anandamide-sensitive CB(1) receptor and GPR55. Overall, it appears that GPR55 has several signaling modalities and that, while anandamide can activate systems containing this receptor, GPR55 cannot yet be primarily designated a receptor for this endocannabinoid.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647110     DOI: 10.1016/S0083-6729(09)81005-4

Source DB:  PubMed          Journal:  Vitam Horm        ISSN: 0083-6729            Impact factor:   3.421


  13 in total

Review 1.  Pharmacological characterization of GPR55, a putative cannabinoid receptor.

Authors:  Haleli Sharir; Mary E Abood
Journal:  Pharmacol Ther       Date:  2010-03-16       Impact factor: 12.310

Review 2.  Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.

Authors:  Simone Tambaro; Marco Bortolato
Journal:  Recent Pat CNS Drug Discov       Date:  2012-04-01

3.  Endogenous cannabinoid signaling is essential for stress adaptation.

Authors:  Matthew N Hill; Ryan J McLaughlin; Brenda Bingham; Lalita Shrestha; Tiffany T Y Lee; J Megan Gray; Cecilia J Hillard; Boris B Gorzalka; Victor Viau
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-03       Impact factor: 11.205

4.  Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.

Authors:  N A Balenga; E Martínez-Pinilla; J Kargl; R Schröder; M Peinhaupt; W Platzer; Z Bálint; M Zamarbide; I G Dopeso-Reyes; A Ricobaraza; J M Pérez-Ortiz; E Kostenis; M Waldhoer; A Heinemann; R Franco
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 5.  Fatty acid amide signaling molecules.

Authors:  Cyrine Ezzili; Katerina Otrubova; Dale L Boger
Journal:  Bioorg Med Chem Lett       Date:  2010-08-13       Impact factor: 2.823

Review 6.  Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.

Authors:  Christopher M Henstridge; Nariman A B Balenga; Julia Kargl; Clara Andradas; Andrew J Brown; Andrew Irving; Cristina Sanchez; Maria Waldhoer
Journal:  Mol Endocrinol       Date:  2011-09-29

7.  The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.

Authors:  Y M AlSuleimani; C R Hiley
Journal:  Br J Pharmacol       Date:  2015-04-24       Impact factor: 8.739

8.  GPR55 ligands promote receptor coupling to multiple signalling pathways.

Authors:  Christopher M Henstridge; Nariman Ab Balenga; Ralf Schröder; Julia K Kargl; Wolfgang Platzer; Lene Martini; Simon Arthur; June Penman; Jennifer L Whistler; Evi Kostenis; Maria Waldhoer; Andrew J Irving
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

Review 9.  The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail.

Authors:  Rebecca Stadel; Kwang H Ahn; Debra A Kendall
Journal:  J Neurochem       Date:  2011-02-11       Impact factor: 5.372

Review 10.  Brain activity of anandamide: a rewarding bliss?

Authors:  Maria Scherma; Paolo Masia; Valentina Satta; Walter Fratta; Paola Fadda; Gianluigi Tanda
Journal:  Acta Pharmacol Sin       Date:  2018-07-26       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.